Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting

Opthea announced the presentation of novel clinical data at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 conference, taking place in Denver, Colorado from May 1-4, 2022 and virtually from May 11-12, 2022.

Jason Slakter, MD, of Vitreous Retina Macula Consultants of New York (VRMNY), will present safety and efficacy data from a prespecified subgroup of patients with polypoidal choroidal vasculopathy (PCV), a common subtype of wet age-related macular degeneration (AMD), that were enrolled in Opthea’s phase 2b clinical trial, which investigated OPT-302 in combination with ranibizumab (Lucentis) compared to ranibizumab alone.

Details for the poster presentation are as follows:

Presentation Title: Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy

Presenter: Jason S. Slakter, MD, Clinical Professor of Ophthalmology at New York University School of Medicine

Presentation Number: F0213

Date and Time: May 1, 2022 from 12:15 PM to 2:15 PM MDT

The ARVO annual conference is recognized as one of the world’s top medical meetings. With more than 10,000 ARVO members worldwide, the annual ARVO meeting hosts leading scientific researchers, clinical investigators and clinicians involved in the ophthalmic industry.